@article{Daskalakis:2023:10.1080/14767058.2022.2160628,
author = {Daskalakis, G and Pergialiotis, V and Domellöf, M and Ehrhardt, H and Di, Renzo GC and Koç, E and Malamitsi-Puchner, A and Kacerovsky, M and Modi, N and Shennan, A and Ayres-de-Campos, D and Gliozheni, E and Rull, K and Braun, T and Beke, A and Kosiska-Kaczyska, K and Areia, AL and Vladareanu, S and Sren, TP and Schmitz, T and Jacobsson, B},
doi = {10.1080/14767058.2022.2160628},
journal = {J Matern Fetal Neonatal Med},
title = {European guidelines on perinatal care: corticosteroids for women at risk of preterm birth.},
url = {http://dx.doi.org/10.1080/14767058.2022.2160628},
volume = {36},
year = {2023}
}

Download

TY  - JOUR
AB  - of recommendationsCorticosteroids should be administered to women at a gestational age between 24+0 and 33+6 weeks, when preterm birth is anticipated in the next seven days, as these have been consistently shown to reduce neonatal mortality and morbidity. (Strong-quality evidence; strong recommendation). In selected cases, extension of this period up to 34+6 weeks may be considered (Expert opinion). Optimal benefits are found in infants delivered within 7 days of corticosteroid administration. Even a single-dose administration should be given to women with imminent preterm birth, as this is likely to improve neurodevelopmental outcome (Moderate-quality evidence; conditional recommendation).Either betamethasone (12 mg administered intramuscularly twice, 24-hours apart) or dexamethasone (6 mg administered intramuscularly in four doses, 12-hours apart, or 12 mg administered intramuscularly twice, 24-hours apart), may be used (Moderate-quality evidence; Strong recommendation). Administration of two "all" doses is named a "course of corticosteroids".Administration between 22+0 and 23+6 weeks should be considered when preterm birth is anticipated in the next seven days and active newborn life-support is indicated, taking into account parental wishes. Clear survival benefit has been observed in these cases, but the impact on short-term neurological and respiratory function, as well as long-term neurodevelopmental outcome is still unclear (Low/moderate-quality evidence; Weak recommendation).Administration between 34 + 0 and 34 + 6 weeks should only be offered to a few selected cases (Expert opinion). Administration between 35+0 and 36+6 weeks should be restricted to prospective randomized trials. Current evidence suggests that although corticosteroids reduce the incidence of transient tachypnea of the newborn, they do not affect the incidence of respiratory distres
AU  - Daskalakis,G
AU  - Pergialiotis,V
AU  - Domellöf,M
AU  - Ehrhardt,H
AU  - Di,Renzo GC
AU  - Koç,E
AU  - Malamitsi-Puchner,A
AU  - Kacerovsky,M
AU  - Modi,N
AU  - Shennan,A
AU  - Ayres-de-Campos,D
AU  - Gliozheni,E
AU  - Rull,K
AU  - Braun,T
AU  - Beke,A
AU  - Kosiska-Kaczyska,K
AU  - Areia,AL
AU  - Vladareanu,S
AU  - Sren,TP
AU  - Schmitz,T
AU  - Jacobsson,B
DO  - 10.1080/14767058.2022.2160628
PY  - 2023///
TI  - European guidelines on perinatal care: corticosteroids for women at risk of preterm birth.
T2  - J Matern Fetal Neonatal Med
UR  - http://dx.doi.org/10.1080/14767058.2022.2160628
UR  - https://www.ncbi.nlm.nih.gov/pubmed/36689999
VL  - 36
ER  - 

Download